ReviewPhysiological reports2021
Maternal microbiome in preeclampsia pathophysiology and implications on offspring health.
Review in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pravastatin in preeclampsia: A meta-analysis and systematic review.Frontiers in medicine · 2022Pooled it
- Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women.Microbiology spectrum · 2024Trial
- Trial
- Maternal and infant gut microbiome.iMeta · 2026Review
- Fermented Foods, Functional Nutrition, and Maternal Gut Microbiota During Pregnancy: Molecular Mechanisms and the Maternal-Infant Microbiome Axis.International journal of molecular sciences · 2026Review
- Monitored food intake in early pregnancy modulates the maternal microbiome in the obese BPH/5 mouse model of superimposed preeclampsia.Physiological genomics · 2026Article
- Preeclampsia and environmental epigenomics: the emerging role of air pollution, gut microbiome, and maternal exposures in disease programming.Environmental epigenetics · 2026Review
- Review
- Vaginal Microbiome and Its Relationship with Assisted Reproduction: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Microbiota Dysbiosis: A Key Modulator in Preeclampsia Pathogenesis and Its Therapeutic Potential.Microorganisms · 2025Review
- The untapped potential of vaginal microbiome diagnostics for improving women's health.Frontiers in cellular and infection microbiology · 2025Review
- Unveiling the placental bacterial microbiota: implications for maternal and infant health.Frontiers in physiology · 2025Review
- PasteurizedMicroorganisms · 2024Article
- Scoping Review of Microbiota Dysbiosis and Risk of Preeclampsia.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024Article
- The Hidden Relationship between Intestinal Microbiota and Immunological Modifications in Preeclampsia Pathogenesis.International journal of molecular sciences · 2024Review
- Microbiota and Recurrent Pregnancy Loss (RPL); More than a Simple Connection.Microorganisms · 2024Review
- Neurodevelopmental Disruptions in Children of Preeclamptic Mothers: Pathophysiological Mechanisms and Consequences.International journal of molecular sciences · 2024Review
- Reducing the Risk of Pre-Eclampsia in Women with Polycystic Ovary Syndrome Using a Combination of Pregnancy Screening, Lifestyle, and Medical Management Strategies.Journal of clinical medicine · 2024Review
- The maternal gut microbiome in pregnancy: implications for the developing immune system.Nature reviews. Gastroenterology & hepatology · 2024Review
- Early life gut microbiome in children following spontaneous preterm birth and maternal preeclampsia.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Preeclampsia is a devastating hypertensive pregnancy disorder that currently affects 2%-8% of pregnancies worldwide. It is associated with maternal and fetal mortality and morbidity and adverse health outcomes both in mom and offspring beyond pregnancy. The pathophysiology is not completely understood, and there are no approved therapies to specifically treat for the disease, with only few therapies approved to manage symptoms. Recent advances suggest that aberrations in the composition of the microbiome may play a role in the pathogenesis of various diseases including preeclampsia. The maternal and uteroplacental environments greatly influence the long-term health outcomes of the offspring through developmental programming mechanisms. The current review summarizes recent developments on the role of the microbiome in adverse pregnancy outcomes with a focus on preeclampsia. It also discusses the potential role of the maternal microbiome in fetal programming; explores gut-targeted therapeutics advancement and their implications in the treatment of preeclampsia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.